Please assess the completion status of the following clinical trial:

Trial Title: Lidocaine for Diabetic Peripheral Neuropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥18;~2. Diagnosis of Diabetes Mellitus (Fasting Plasma Glucose \> 126 mg/dL and/or HbA1C \>6.5%);~3. Distal symmetric pain in lower extremities with duration of more than 3 months;~4. Presence of either numbness or at least 1 sensory disturbance (increased or decreased sensitivity) in the feet.~5. Spontaneous pain with intensity of ≥ 4 on 0-10 Numerical Rating Scale (NRS).~Exclusion Criteria:~1. Not giving consent to participate in the study;~2. Unable to complete self-report pain questionnaire;~3. History of moderate to severe renal or liver failure;~4. History of other central or peripheral neurologic disorders;~5. History of cardiac arrhythmias;~6. Contraindication to intravenous lidocaine;~7. Pregnancy or lactation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Normal saline infusion then lidocaine infusion (Type: PLACEBO_COMPARATOR): Intravenous infusion of normal saline over a 40 minute period. second intervention: Intravenous infusion of lidocaine \[5mg/kg\] over a 40 minute period.
- Lidocaine infusion, then normal saline infusion (Type: ACTIVE_COMPARATOR): Intravenous infusion of lidocaine \[5mg/kg\] over a 40 minute period. second intervention: Intravenous infusion of normal saline over a 40 minute period.

Based on this trial design, predict the completion outcome and termination type (if applicable).